Show simple item record

dc.contributor.authorMcNamara, Mairead G
dc.contributor.authorBridgewater, J
dc.contributor.authorPalmer, D
dc.contributor.authorWasan, H
dc.contributor.authorRyder, W David J
dc.contributor.authorGnanaranjan, C
dc.contributor.authorGhazaly, E
dc.contributor.authorEvans, T
dc.contributor.authorValle, Juan W
dc.date.accessioned2019-04-29T09:49:01Z
dc.date.available2019-04-29T09:49:01Z
dc.date.issued2018en
dc.identifier.citationMcNamara MG, Bridgewater J, Palmer D, Wasan H, Ryder WD, Gnanaranjan C, et al. 758P A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08). Ann Oncol. 2018;29(suppl_8):259.en
dc.identifier.doi10.1093/annonc/mdy282.141en
dc.identifier.urihttp://hdl.handle.net/10541/621803
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy282.141en
dc.titleA new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record